glp-1 + nad+ Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update What Older Adults Should Know

[DOI] [PubMed] [Google Scholar] 8.Incretin-based drugs and intestinal obstruction: a pharmacovigilance study

Who must avoid it entirely in the class framing: anyone pregnant or breastfeeding, anyone with the personal/family MTC or MEN 2 history above, and anyone with prior serious hypersensitivity to a GLP-1 agonist

We can often avoid some of those side effects if we increase the dose slowly and not just increase the dose once a month

Substance-use disorders Pre-clinical and mechanistic studies A large body of pre-clinical and mechanistic literature is available regarding the putative effects of GLP-1RAs on substance misuse (Supplementary Section 5): 24 for alcohol 59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82 , 8 for opiates 63,83,84,85,86,87,88,89 , 16 for stimulants, including cocaine and amphetamines 90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105 , and 4 for nicotine 106,107,108,109